Price history
¥2,268Latest+101.4%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
A summary lands here once the filings have been read.
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 18
PER
23.18How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.PBR
1.45How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
6.3%Earning power. A figure above 10% is generally considered good.Dividend yield
0.0%The annual dividend as a percentage of the share price.Market capitalization
¥10bnShare price × number of shares. The value of the entire company.Equity ratio
79.3%The proportion of assets funded by money that does not have to be repaid.Operating margin
14.2%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
4.1%The average annual growth in sales over the past three years.What to watch next
Automated reagent filling equipment at the Kasama Plant: commissioning scheduled for March 2026, with capacity expected to increase by 23% after completion
Around March 2026Impact HighLikelihood Medium
Whether the transition from “early adoption to market share expansion” for the procalcitonin kit, LATECLE PCT reagent, is reflected in sales and earnings, including the product’s contribution and guidance in financial results
The next full-year or interim results, from the second half of 2025 through 2026Impact MediumLikelihood Medium
Immunoassay reagents for Sysmex measurement platforms: additional target reagents, new product launches, and sales expansion, including expansion beyond the areas launched in 2024
Through 2026Impact MediumLikelihood Low
The sales ramp-up for new products and launches in the transfusion testing field, such as Grifols sCD38 and related reagents
From 2026 onward, depending on when sales begin to be reflected following the launchesImpact LowLikelihood Low
What to watch next
Who owns itTop holders total 66.6%
Listed holders 66.6%Everyone else 33.4%
Asahi Kasei Pharma Corporation21.13%
Sugiyama Akiko (杉山 晶子)10.00%
UH Partners 2 Co., Ltd.7.51%
HIKARI TSUSHIN,INC.7.35%
Custody Bank of Japan, Ltd.5.25%
SYSMEX CORPORATION5.17%
KAINOS employee stock ownership plan4.38%
株式会社UH Partners 32.54%
2 other listed holders3.24%
| Holder | Ownership (%) |
|---|---|
| Asahi Kasei Pharma Corporation | 21.13 |
| Sugiyama Akiko (杉山 晶子) | 10.00 |
| UH Partners 2 Co., Ltd. | 7.51 |
| HIKARI TSUSHIN,INC. | 7.35 |
| Custody Bank of Japan, Ltd. | 5.25 |
| SYSMEX CORPORATION | 5.17 |
| KAINOS employee stock ownership plan | 4.38 |
| 株式会社UH Partners 3 | 2.54 |
| 2 other listed holders | 3.24 |
This company's documents
Filings
Timely disclosures
- 2026-06-10Notice of the Delisting of Our Shares
- 2026-05-25Articles of Incorporation 2026/06/15
- 2026-05-25Notice Regarding Approval Resolutions on a Share Consolidation, the Abolition of the Provisions on the Number of Shares per Trading Unit, and Partial Amendments to the Articles of Incorporation
- 2026-05-08Financial Results for the Fiscal Year Ending March 2026 [Japanese GAAP] (Non-consolidated)
- 2026-05-08Statutory Prior Disclosure Document (Share Consolidation)
- 2026-05-01Notice of Convocation of the 2026 Extraordinary General Meeting of Shareholders
- 2026-04-22Notice Concerning the Cancellation of Treasury Shares
- 2026-04-22Notice Concerning a Share Consolidation, the Abolition of the Share Unit System and Partial Amendments to the Articles of Incorporation
2 more
- 2026-03-26Notice Regarding the Setting of a Record Date for the Convocation of an Extraordinary General Meeting of Shareholders
- 2026-03-26Notice of the Results of the Tender Offer for the Company's Shares by Flowers株式会社 and Changes in the Parent Company, Largest Shareholder Among the Major Shareholders, and Major Shareholders